Track ACADIA Pharmaceuticals Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ACADIA Pharmaceuticals Inc. ACAD · Stock Open ACADIA Pharmaceuticals Inc. in new tab

18.75 USD
P/E
8.84
EPS
2.12
P/B
2.33
ROE
31.43
Beta
0.89
Target Price
30.53 USD
ACADIA Pharmaceuticals Inc. logo

ACADIA Pharmaceuticals Inc.

🧾 Earnings Recap – Q3 2026

Acadia reported higher third-quarter revenue and raised DAYBUE guidance, while its Phase II RADIANT study narrowly missed statistical significance on the primary endpoint. Shares fell 1.1% after earnings, a roughly flat reaction.

  • Total revenue was $342 million, up 22% year over year on an adjusted basis.
  • DAYBUE sales reached a record $140 million, up 39%; management raised 2026 DAYBUE guidance.
  • NUPLAZID sales were $202 million, up 12% on an adjusted basis, with growth driven largely by patient demand through volume.
  • RADIANT’s Phase II portion narrowly missed statistical significance on its primary endpoint; Acadia plans to focus the Phase III program on the 60-milligram dose.
  • Acadia expects ILLUMERA Phase II results in LBD psychosis in the fourth quarter of 2027, while an additional NORLIGHT readout is now expected in the second half of 2027.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E8.84
EPS2.12
Book Value8.03
Price to Book2.33
Debt/Equity5.18
% Insiders0.331%
Growth
Revenue Growth0.23%
Earnings Growth-0.26%
Estimates
Forward P/E17.09
Forward EPS1.10
Target Mean Price30.53

DCF valuation

Model fair value for ACADIA Pharmaceuticals Inc. (ACAD)
Result
Sign in to run the valuation for ACAD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Buy · mean target 30.53 USD (low 16.00, high 38.00) · as of 14 Nov 2026
Low 16.00
Mean 30.53
High 38.00
Price 18.75
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ACADIA Pharmaceuticals Inc. Logo ACADIA Pharmaceuticals Inc. Analysis (ACAD)

United States Health Care Official Website Stock

Is ACADIA Pharmaceuticals Inc. a good investment? ACADIA Pharmaceuticals Inc. (ACAD) is currently trading at 18.75 USD. Market analysts have a consensus price target of 30.53 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 8.84. This relatively low multiple may signal that ACADIA Pharmaceuticals Inc. is undervalued compared to historical market norms.

Earnings Schedule: ACADIA Pharmaceuticals Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 1.10.

Investor FAQ

Does ACADIA Pharmaceuticals Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ACADIA Pharmaceuticals Inc.?

ACADIA Pharmaceuticals Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 2.12.

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Exchange Ticker
STU (Germany) DR6.SG
MEX (Mexico) ACAD.MX
FRA (Germany) DR6.F
NMS (United States) ACAD
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion